Samuel Sarkodie
Professor James Wason
Dr Michael Grayling
| A hybrid approach to sample size re-estimation in cluster randomized trials with continuous outcomes | 2024 |
|
Professor James Wason
| Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people | 2024 |
|
Dr George Mells
Professor David Jones
Professor James Wason
Shaun Hiu
Dorcas Kareithi
et al. | COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls | 2024 |
|
Dr Svetlana Cherlin
Professor James Wason
| Cross-validated risk scores adaptive enrichment (CADEN) design | 2024 |
|
Dr Nicola Wyatt
Dr Hannah Watson
Dr Dean Allerton
Michelle Bardgett
Dr Emma Clark
et al. | Defining predictors of responsiveness to advanced therapies in Crohn’s disease and ulcerative colitis: Protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine | 2024 |
|
Professor Andrew Fisher
Professor Helen Hancock
Professor James Wason
Dr Michael Grayling
Dr Joanne Lally
et al. | Extracorporeal Photopheresis (ECP) in the Treatment of Chronic Lung Allograft Dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK) | 2024 |
|
Dr Faye Wolstenhulme
Irena Bibby
Mike Cole
Lydia Grixti
Dr Naomi McGregor
et al. | Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves' disease | 2024 |
|
Professor James Wason
| Multidisciplinary considerations for implementing Bayesian borrowing in basket trials | 2024 |
|
Dr Leher Gumber
Dr Opeyemi Agbeleye
Alex Inskip
Ross Fairbairn
Madeleine Still
et al. | Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions | 2024 |
|
Dr James Lordan
Dr Moha Shojaei
Dr Nan Lin
Professor James Wason
| Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies | 2024 |
|
Humayra Dervin
Emma Belilios
Professor James Wason
Catherine McParlin
Dr Andrew Sims
et al. | Using a prognostic medical device for early identification of pressure ulcers: protocol for study design | 2024 |
|
Dr Svetlana Cherlin
Dr Theophile Bigirumurame
Dr Michael Grayling
Dr Jérémie Nsengimana
Luke Ouma
et al. | Utilising high-dimensional data in randomised clinical trials: a review of methods and practice | 2024 |
|
Samuel Sarkodie
Professor James Wason
Dr Michael Grayling
| A hybrid approach to comparing parallel-group and stepped-wedge cluster-randomized trials with a continuous primary outcome when there is uncertainty in the intra-cluster correlation | 2023 |
|
Professor James Wason
| A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol | 2023 |
|
Lou Whitehead
Professor Miles Witham
Professor James Wason
| Bayesian borrowing for basket trials with longitudinal outcomes | 2023 |
|
Dr Haiyan Zheng
Dr Michael Grayling
Professor James Wason
| Bayesian sample size determination in basket trials borrowing information between subsets | 2023 |
|
Dr Haiyan Zheng
Professor James Wason
| Bayesian sample size determination using commensurate priors to leverage preexperimental data | 2023 |
|
Dr Theophile Bigirumurame
Shaun Hiu
Professor Dawn Teare
Professor James Wason
Andrew Bryant
et al. | Current practices in studies applying the target trial emulation framework: a protocol for a systematic review | 2023 |
|
Professor James Wason
| Discussion on "Adaptive enrichment designs with a continuous biomarker" by Nigel Stallard | 2023 |
|
Dr Miranda Patterson
Dr Nina Wilson
Tara Homer
Laura Simms
Dr Alison Steel
et al. | Dual bronchodilators in Bronchiectasis study (DIBS): protocol for a pragmatic, multicentre, placebo-controlled, three-arm, double-blinded, randomised controlled trial studying bronchodilators in preventing exacerbations of bronchiectasis | 2023 |
|
Professor James Wason
Dr Faye Williamson
| Medicines and Healthcare products Regulatory Agency’s “Consultation on proposals for legislative changes for clinical trials”: a response from the Trials Methodology Research Partnership Adaptive Designs Working Group, with a focus on data sharing | 2023 |
|
Professor James Wason
| Online error rate control for platform trials | 2023 |
|
Professor James Wason
| Online Multiple Hypothesis Testing | 2023 |
|
Dr Michael Grayling
Professor James Wason
| Point estimation following a two-stage group sequential trial | 2023 |
|
Professor James Wason
| A two-stage drop-the-losers design for time-to-event outcome using a historical control arm | 2022 |
|
Aritra Mukherjee
Dr Michael Grayling
Professor James Wason
| Adaptive designs: Benefits and cautions for neurosurgery trials | 2022 |
|
Helen Mossop
Dr Michael Grayling
Professor James Wason
| Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials | 2022 |
|
Luke Ouma
Dr Michael Grayling
Professor James Wason
Dr Haiyan Zheng
| Bayesian modelling strategies for borrowing of information in randomised basket trials | 2022 |
|
Dr Haiyan Zheng
Professor James Wason
| Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy | 2022 |
|
Dr Guy Taylor
Andy Shaw
Kieran Smith
Professor James Wason
Professor Emma Stevenson
et al. | Capturing the real-world benefit of residual β-cell function during clinically important time-periods in established Type 1 diabetes | 2022 |
|
Professor James Wason
| Components of smartphone cognitive-behavioural therapy for subthreshold depression among 1093 university students: a factorial trial | 2022 |
|
Dr Michael Grayling
Professor James Wason
| Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials | 2022 |
|
Luke Ouma
Professor James Wason
Dr Haiyan Zheng
Dr Nina Wilson
Dr Michael Grayling
et al. | Design and analysis of umbrella trials: Where do we stand? | 2022 |
|
Professor James Wason
| Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis | 2022 |
|
Professor James Wason
| Determining the OPTIMAL DTI analysis method for application in cerebral small vessel disease | 2022 |
|
Professor James Wason
| Effects of Exercise and Sleep Deprivation on Reaction Severity During Oral Peanut Challenge: A Randomized Controlled Trial | 2022 |
|
Dr Holly Fisher
Shaun Hiu
Dorcas Kareithi
Professor David Jones
Professor James Wason
et al. | Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls | 2022 |
|
Professor James Wason
| Imaging Glioblastoma Metabolism by Using Hyperpolarized [1-13C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study | 2022 |
|
Dr Michael Grayling
Professor Rakesh Heer
Professor James Wason
| Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials | 2022 |
|
Dr Kate Rennie
Professor Miles Witham
Penny Bradley
Professor Helen Hancock
Shaun Hiu
et al. | MET-PREVENT: metformin to improve physical performance in older people with sarcopenia and physical prefrailty/frailty - protocol for a double-blind, randomised controlled proof-of-concept trial | 2022 |
|
Professor James Wason
Dr Nina Wilson
Professor Helen Hancock
Rebecca Maier
| Practical guidance for planning resources required to support publicly-funded adaptive clinical trials | 2022 |
|
Professor James Wason
| Prediction of dementia using diffusion tensor MRI measures: the OPTIMAL collaboration | 2022 |
|
Professor James Wason
Dr Arthur Pratt
Professor John Isaacs
Dr Elena Nikiphorou
| Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter? | 2022 |
|
Dr Michael Grayling
Professor James Wason
| Response adaptive intervention allocation in stepped-wedge cluster randomized trials | 2022 |
|
Dr Jessica Barrett
Professor James Wason
| Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints | 2022 |
|
Dr Theophile Bigirumurame
Germain Uwimpuhwe
Professor James Wason
| Sequential multiple assignment randomized trial studies should report all key components: a systematic review | 2022 |
|
Dr Faye Williamson
Dr Michael Grayling
Professor James Wason
| Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information | 2022 |
|
Professor James Wason
Dr Arthur Pratt
Professor John Isaacs
| The role of comorbidities alongside patient and disease characteristics on long-term disease activity in RA using UK inception cohort data | 2022 |
|
Professor James Wason
| Two-stage penalized regression screening to detect biomarker–treatment interactions in randomized clinical trials | 2022 |
|
Aritra Mukherjee
Professor James Wason
Dr Michael Grayling
| When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay | 2022 |
|
Dr Dennis Lendrem
Dr Jessica Tarn
Professor James Wason
Professor Fai Ng
| Why stratification is important in primary Sjögren’s syndrome | 2022 |
|
Dr Michael Grayling
Professor James Wason
| A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials | 2021 |
|
Professor James Wason
| Bayesian design and analysis of external pilot trials for complex interventions | 2021 |
|
Professor James Wason
| Controlling type I error rates in multi‐arm clinical trials: A case for the false discovery rate | 2021 |
|
Dr Nina Wilson
Rebecca Maier
Professor Helen Hancock
Professor James Wason
| Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project | 2021 |
|
Dr Svetlana Cherlin
Professor James Wason
| Developing a predictive signature for two trial endpoints using the cross-validated risk scores method | 2021 |
|
Professor James Wason
| Employing a latent variable framework to improve efficiency in composite endpoint analysis | 2021 |
|
Dr Michael Grayling
Professor James Wason
| Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables | 2021 |
|
Professor James Wason
| Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients | 2021 |
|
Dr Michael Grayling
Professor James Wason
| Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial | 2021 |
|
Dr Michael Grayling
Dr Theophile Bigirumurame
Dr Svetlana Cherlin
Luke Ouma
Dr Haiyan Zheng
et al. | Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential | 2021 |
|
Dr Svetlana Cherlin
Professor James Wason
| Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial | 2021 |
|
Dr Alexis Collins
Dr Dennis Lendrem
Professor James Wason
Dr Jessica Tarn
Dr Nadia Howard-Tripp
et al. | Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine | 2021 |
|
Professor James Wason
| Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats | 2021 |
|
Luke Ouma
Dr Michael Grayling
Dr Haiyan Zheng
Professor James Wason
| Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods | 2021 |
|
Professor James Wason
| A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints | 2020 |
|
Dr Michael Grayling
Professor James Wason
| A web application for the design of multi-arm clinical trials | 2020 |
|
Professor James Wason
| Analysis of responder-based endpoints: improving power through utilising continuous components | 2020 |
|
Professor Miles Witham
Professor James Wason
Dr Richard Dodds
Professor Avan Sayer
| Developing a composite outcome measure for frailty prevention trials – rationale, derivation and sample size comparison with other candidate measures | 2020 |
|
Professor Miles Witham
Ella Anderson
Kimberley Down
Rebecca Maier
Dr Gary Nestor
et al. | Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process | 2020 |
|
Dr Svetlana Cherlin
Professor James Wason
| Developing and testing high‐efficacy patient subgroups within a clinical trial using risk scores | 2020 |
|
Professor James Wason
Dr Faye Williamson
| Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19 | 2020 |
|
Professor James Wason
| Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold. | 2020 |
|
Professor Miles Witham
Ella Anderson
Kimberley Down
Rebecca Maier
Dr Gary Nestor
et al. | Ensuring that COVID-19 research is inclusive: guidance from the NIHR INCLUDE project | 2020 |
|
Professor James Wason
| Graphical approaches for the control of generalized error rates | 2020 |
|
Professor James Wason
| Imaging breast cancer using hyperpolarized carbon-13 MRI | 2020 |
|
Professor James Wason
| Including non-concurrent control patients in the analysis of platform trials: is it worth it? | 2020 |
|
Professor James Wason
| Mentalization for Offending Adult Males (MOAM): study protocol for a randomized controlled trial to evaluate mentalization-based treatment for antisocial personality disorder in male offenders on community probation | 2020 |
|
Christopher Bojke
Professor James Wason
| Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT): study protocol for a randomised controlled trial | 2020 |
|
Dr David Cottrell
Professor James Wason
| Multisystemic therapy compared with management as usual for adolescents at risk of offending: the START II RCT | 2020 |
|
Dr David Cottrell
Professor James Wason
| Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): 5-year follow-up of a pragmatic, randomised, controlled, superiority trial | 2020 |
|
Professor James Wason
| Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals | 2020 |
|
Professor James Wason
| Simple MRI scores aids prediction of dementia in cerebral small vessel disease | 2020 |
|
Professor James Wason
| The Adaptive designs CONSORT Extension (ACE) Statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design | 2020 |
|
Dr Michael Grayling
Professor James Wason
| Admissible multiarm stepped-wedge cluster randomized trial designs | 2019 |
|
Professor James Wason
| Effect of sleep deprivation and exercise on reaction threshold in adults with peanut allergy: A randomized controlled study | 2019 |
|
Professor James Wason
| Familywise error control in multi-armed response-adaptive trials | 2019 |
|
Professor James Wason
| Overestimated treatment effects in randomised phase II trials: What's up doctor? | 2019 |
|
Professor James Wason
| To add or not to add a new treatment arm to a multi-arm study: a decision-theoretic framework | 2019 |
|
Dr Michael Grayling
Professor James Wason
| Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies | 2019 |
|
Professor James Wason
| When to keep it simple - adaptive designs are not always useful | 2019 |
|
Professor James Wason
| Adaptive designs in clinical trials: why use them, and how to run and report them | 2018 |
|
Dr Michael Grayling
Professor James Wason
| An optimised multi-arm multi-stage clinical trial design for unknown variance | 2018 |
|
Dr Michael Grayling
Professor James Wason
| Blinded and unblinded sample size re-estimation in crossover trials balanced for period | 2018 |
|
Dr Michael Grayling
Professor James Wason
| Blinded and unblinded sample size reestimation procedures for stepped-wedge cluster randomized trials | 2018 |
|
Dr Michael Grayling
Professor James Wason
| Group Sequential Clinical Trial Designs for Normally Distributed Outcome Variables | 2018 |
|
Dr Michael Grayling
Professor James Wason
| Group sequential crossover trial designs with strong control of the familywise error rate | 2018 |
|
Professor James Wason
| Improving the analysis of composite endpoints in rare disease trials | 2018 |
|
Professor James Wason
| Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study | 2018 |
|
Dr David Cottrell
Professor James Wason
| Multisystemic Therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): a randomised controlled pragmatic effectiveness superiority trial | 2018 |
|
Professor James Wason
| Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends? | 2018 |
|
Professor James Wason
| A multi-stage drop-the-losers design for multi-arm clinical trials | 2017 |
|
Dr Michael Grayling
Professor James Wason
| Group sequential designs for stepped-wedge cluster randomised trials | 2017 |
|
Dr Ross Maxwell
Professor James Wason
| Imaging biomarker roadmap for cancer studies | 2017 |
|
Professor James Wason
| Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements | 2017 |
|
Dr Michael Grayling
Professor James Wason
| Stepped wedge cluster randomized controlled trial designs: A review of reporting quality and design features | 2017 |
|
Professor James Wason
| The longitudinal effect of ejaculation on seminal vesicle fluid volume and whole-prostate ADC as measured on prostate MRI | 2017 |
|
Professor James Wason
| Two-stage phase II oncology designs using short-term endpoints for early stopping | 2017 |
|
Professor James Wason
| A review of statistical designs for improving the efficiency of phase II studies in oncology | 2016 |
|
Professor James Wason
| An adaptive design for updating the threshold value of a continuous biomarker | 2016 |
|
Professor James Wason
| HLA associations in South Asian multiple sclerosis | 2016 |
|
Professor James Wason
| Improving outcomes in adults with epilepsy and intellectual disability (EpAID) using a nurse-led intervention: study protocol for a cluster randomised controlled trial | 2016 |
|
Professor James Wason
| Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: an application of the augmented binary method | 2016 |
|
Professor James Wason
| Some recommendations for multi-arm multi-stage trials | 2016 |
|
Professor James Wason
| Use of an embedded, micro-randomised trial to investigate non-compliance in telehealth interventions | 2016 |
|
Professor James Wason
| A Bayesian adaptive design for biomarker trials with linked treatments | 2015 |
|
Professor James Wason
| Evaluation of multisystemic therapy pilot services in Services for Teens Engaging in Problem Sexual Behaviour (STEPS-B): study protocol for a randomized controlled trial | 2015 |
|
Professor James Wason
| Multi-armed bandit models for the optimal design of clinical trials: Benefits and challenges | 2015 |
|
Professor James Wason
| Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax | 2015 |
|
Professor James Wason
| OptGS – An R package for finding near-optimal group-sequential designs. | 2015 |
|
Professor James Wason
| Prospective study evaluating the relative sensitivty of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design | 2015 |
|
Professor James Wason
| Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule | 2015 |
|
Professor James Wason
| The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected | 2015 |
|
Professor James Wason
| The power of phase II end-points for different possible mechanisms of action of an experimental treatment | 2015 |
|
Professor James Wason
| A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials | 2014 |
|
Professor James Wason
Janice Dunn
| Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. | 2014 |
|
Professor James Wason
| Comment on: Month of birth and risk of multiple sclerosis: confounding and adjustments | 2014 |
|
Professor James Wason
| Confounding in association studies: Month of birth and multiple sclerosis | 2014 |
|
Professor James Wason
| Correcting for multiple-testing in multi-arm trials: Is it necessary and is it done? | 2014 |
|
Professor James Wason
| Design of telehealth trials - Introducing adaptive approaches | 2014 |
|
Professor James Wason
| Recent developments in group-sequential designs | 2014 |
|
Professor James Wason
| A "Candidate-Interactome" Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis | 2013 |
|
Professor James Wason
| Confounding underlies the apparent month of birth effect in multiple sclerosis | 2013 |
|
Dr David Cottrell
Professor James Wason
| Evaluation of multisystemic therapy pilot services in the Systemic Therapy for At Risk Teens (START) trial: Study protocol for a randomised controlled trial | 2013 |
|
Professor James Wason
| Planning multi-arm screening studies within the context of a drug development program | 2013 |
|
Professor James Wason
| Reducing the average number of patients needed in a phase II trial through novel design | 2013 |
|
Professor James Wason
| The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma | 2013 |
|
Professor James Wason
| Using continuous data on tumour measurements to improve inference in phase II cancer studies | 2013 |
|
Professor James Wason
| A General framework for two-stage analysis of genome-wide association studies and its application to case-control studies | 2012 |
|
Professor James Wason
| Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis | 2012 |
|
Professor James Wason
| Identifying combined design and analysis procedures in two-stage trials with a binary end point | 2012 |
|
Professor James Wason
| Optimal design of multi-arm multi-stage trials | 2012 |
|
Professor James Wason
| Optimal multistage designs for randomised clinical trials with continuous outcomes | 2012 |
|
Professor James Wason
| Risk in complex genetics: "all models are wrong but some are useful" | 2012 |
|
Professor James Wason
| Stage phase II clinical trials with continuous outcomes | 2012 |
|
Professor James Wason
| Accelerated BEP: A phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour | 2011 |
|
Professor James Wason
| Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis | 2011 |
|
Professor James Wason
| Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points | 2011 |
|
Professor James Wason
| A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis | 2010 |
|
Professor James Wason
| Comparison of multimarker logistic regression models, with application to a genomewide scan of schizophrenia | 2010 |
|
Professor James Wason
| What role for genetics in the prediction of multiple sclerosis? | 2010 |
|
Professor James Wason
| Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor | 2009 |
|
